{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:53Z","timestamp":1792787813912,"version":"4.5.0"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Duke University Office of the Provost","id":[{"id":"https:\/\/ror.org\/00py81415","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Duke-UNC Alzheimer\u2019s Disease Research Center","award":["NIA P30AG072958"],"award-info":[{"award-number":["NIA P30AG072958"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-amyloid immunotherapies are approved by the United States Food and Drug Administration for the treatment of Alzheimer's disease; however, the adoption and safety profile of these medications in routine clinical practice have not been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the adoption and safety profile of anti-amyloid immunotherapies in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective observational cohort study using target trial emulation methods. The data source was nationwide electronic health record data from Epic Cosmos. The primary exposure was the first prescription of anti-amyloid immunotherapy versus the active comparator of oral dementia therapy (acetylcholinesterase inhibitor (AChEI) or memantine, selected to minimize bias by baseline health status and disease severity). The primary end point was time to first nontraumatic intracranial hemorrhage (ICH). Propensity score overlap weighting was used to balance baseline demographic and clinical characteristics across treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between July 1, 2023 and January 1, 2025, 2616 patients (median age 74.8 years [IQR 69.8\u201378.8]; 53.9% female) were prescribed anti-amyloid immunotherapy (with or without AChEI\/memantine), and 1,065,192 patients (median age 79.98 [IQR 73.6\u201385.6], 57.9% female) were prescribed AChEI\/memantine alone. In total, 401 patients prescribed anti-amyloid immunotherapy and 274,470 patients prescribed AChEI\/memantine were assessed for safety endpoints. Compared with AChEI\/memantine, the analysis did not detect a statistically significant association between prescription of anti-amyloid immunotherapy and ICH (owHR 0.73 [95% CI 0.10\u20135.12]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study did not detect a statistically significant association between prescription of anti-amyloid immunotherapy and ICH. The small treated cohort and low event count yielded imprecise estimates; these findings do not confirm safety and cannot exclude a clinically important increase in risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823261483526","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:35:47Z","timestamp":1790753747000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Uptake and safety profile of anti-amyloid immunotherapies in routine clinical practice"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5728-8872","authenticated-orcid":false,"given":"Jay B.","family":"Lusk","sequence":"first","affiliation":[{"name":"Departments of Neurology and Internal Medicine, University of Texas Southwestern Medical Center"},{"name":"Department of Family Medicine, University of North Carolina, Chapel Hill, NC, USA"},{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"},{"name":"Department of Health Economics, Systems, and Policy, Peter J. O'Donnel l Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-4608","authenticated-orcid":false,"given":"Kate Vinita","family":"Fitch","sequence":"additional","affiliation":[{"name":"University of North Carolina-Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-2489","authenticated-orcid":false,"given":"Kim G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Duke University"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Liu","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[{"name":"University of North Carolina-Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine E.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McDevitt","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"},{"name":"Washington University"},{"name":"Washington University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-1680","authenticated-orcid":false,"given":"Anqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Whitson","sequence":"additional","affiliation":[{"name":"Duke University"},{"name":"Geriatrics Research Education and Clinical Center, Durham VA Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Aymes","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-6434","authenticated-orcid":false,"given":"Bradley G.","family":"Hammill","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8419","authenticated-orcid":false,"given":"Brian","family":"Mac Grory","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-3673","authenticated-orcid":false,"given":"Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Hub, Duke University, Durham, NC, USA"},{"name":"Duke University"},{"name":"Duke University"},{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_4_2","unstructured":"U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer\u2019s disease https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease (2024 accessed 19 July 2025)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11704"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11703"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11702"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11701"},{"key":"e_1_3_3_11_2","article-title":"Real-world\u2019 eligibility for anti-amyloid treatment in a tertiary memory clinic setting","volume":"21","author":"Vigneswaran S","year":"2025","unstructured":"Vigneswaran S, Vijverberg EGB, Barkhof F, et al. Real-world\u2019 eligibility for anti-amyloid treatment in a tertiary memory clinic setting. Alzheimers Dement 2025; 21: e70375.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333468"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100102"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083034"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1033"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201400"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa223"},{"key":"e_1_3_3_19_2","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li F","year":"2019","unstructured":"Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 2019; 188: 250\u2013257.","journal-title":"Am J Epidemiol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwad151"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_3_24_2","unstructured":"Lumley T. Survey: analysis of complex survey samples https:\/\/cran.r-project.org\/web\/packages\/survey\/index.html (2025 accessed 3 September 2025)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr597"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26819"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13803"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1346621"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14467"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4693"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00748-0"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12891"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200273"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14067"},{"key":"e_1_3_3_36_2","first-page":"773","article-title":"Assessment of disparities in timely diagnosis and comprehensive workup of cognitive impairment between English and Spanish speakers","volume":"32","author":"Silva-Rudberg JA","year":"2024","unstructured":"Silva-Rudberg JA, Carri\u00f3n CI, P\u00e9rez-Palmer N, et al. Assessment of disparities in timely diagnosis and comprehensive workup of cognitive impairment between English and Spanish speakers. Am J Geriatr Psychiatry 2024; 32: 773\u2013786.","journal-title":"Am J Geriatr Psychiatry"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213483"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230009"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100015"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261483526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823261483526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261483526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:35:49Z","timestamp":1790753749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823261483526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["10.1177\/25424823261483526"],"URL":"https:\/\/doi.org\/10.1177\/25424823261483526","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"25424823261483526"}}